sulfamethoxazole has been researched along with Tuberculosis, Multidrug-Resistant in 2 studies
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.
Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients." | 5.43 | Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016) |
| " However, only limited data are available on the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of co-trimoxazole in TB patients." | 1.43 | Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis. ( Akkerman, OW; Alffenaar, JW; Alsaad, N; de Lange, WC; Dijkstra, JA; Kosterink, JG; van der Werf, TS; van Soolingen, D, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsaad, N | 1 |
| Dijkstra, JA | 1 |
| Akkerman, OW | 1 |
| de Lange, WC | 1 |
| van Soolingen, D | 1 |
| Kosterink, JG | 1 |
| van der Werf, TS | 1 |
| Alffenaar, JW | 1 |
| Vilchèze, C | 1 |
| Jacobs, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis[NCT01832987] | Phase 2 | 12 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for sulfamethoxazole and Tuberculosis, Multidrug-Resistant
| Article | Year |
|---|---|
Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Female; Humans; Male; Microbial Sensitivity Tes | 2016 |
The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.
Topics: Anaerobiosis; Anti-Bacterial Agents; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculo | 2012 |